May 23, 2013
/PRNewswire/ -- PuraMed BioScience
, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.
- Non-Prescription, All Natural Product to Treat Migraine Headaches
- Clinical Trials Show the Product Outperforms #1 Prescription Competitor
- Currently Available Nationwide at Walgreen's and CVS/pharmacy stores
- Launching Marketing and Distribution Campaign
- Expanding Retail-Chain-Store Distribution
- Holds Patent on Product
- 38 Million Shares Outstanding
- Market Cap just under $1 Million
May 14, 2013
, PuraMed BioScience had approximately 37.9 million common shares outstanding, thus giving the stock a market cap valuation of an estimated
PuraMed BioScience currently has LipiGesic
M, an over-the-counter migraine pain reliever, distributed in Walgreens and CVS/pharmacy stores nationwide. The Company plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as selected regional drugstore chains.
With an estimated 39 million Americans suffering from migraine headaches, the revenue prospects for PuraMed BioScience could be explosive.
"The first thing to consider is that people who suffer the excruciating pain of migraine are actively looking for a product that will relieve their migraine pain and associated symptoms," said
, CEO of PuraMed BioScience. "The second point to consider is that LipiGesic M has been shown to be highly effective and works as well as the number-one-selling prescription migraine treatment without the severe side effects often caused by chemical compounds. Since it is an OTC product, LipiGesic M is available without a doctor's prescription at far less cost. This availability will be increasingly important as insurance premiums, co-pays and deductibles continue to rise in response to changes prompted by the Affordable Care Act."
Thus, if PMBS gains 1% of the migraine market that would result in approximately 400,000 consumers buying LipiGesic M at a retail price of
; that equates to nearly
In addition, consumers with acute migraines that recur two to three times a month who find LipiGesic M an effective migraine relief product would be expected to buy nine (9) boxes per year creating a potential of
in annual sales.
These numbers are calculated based on just 1% of the migraine market.